Numerous North Carolina companies are contributing to the production of COVID-19 vaccines, therapies, diagnostics and protection devices. He also championed the Merck site saying, “The Durham plant plays a tremendous role in controlling the global spread of preventable diseases, It’s an impressive example of the strength and diversity of this state’s biotechnology and pharmaceutical sector.” “This growing cluster of biomanufacturing companies serves a global need that will only continue to require more of what our outstanding workforce can provide,” “North Carolina’s long-term investment in the life sciences is not just good for our state,” he noted. And the growth is on the way in the form of a $650 million, 225,000-square-foot addition, where the company will manufacture the active ingredient for Merck’s recombinant human papillomavirus (HPV) vaccine.īill Bullock, the North Carolina Biotechnology Center’s senior vice president, Economic Development and Statewide Operations, lauded Merck’s decision to produce the J&J vaccine in Durham as a win-win for the world. Its 900,000-plus square feet of real estate houses the production of a wide range of Merck products. The selection of the 262-acre Durham site comes at a time of expansion there, with investment approaching $2 billion. That’s in addition to the government’s previous agreement to purchase an initial 100 million units. President Joe Biden announced earlier this week a government deal to secure 100 million more doses of J&J’s COVID-19 vaccine. The Defense Production Act speeds access to materials needed for production. Department of Health and Human Services, the parent agency for BARDA. Merck will receive $105 million from BARDA initially through the Defense Production Act, according to a release issued by the U.S. The government’s Biomedical Advanced Research and Development Authority (BARDA) will allocate up to $268.8 million to upgrade the two Merck locations to manufacture the single-dose J&J vaccine. The company’s huge West Point, Pennsylvania site will fill vaccine vials with finished product and package them for shipment. Merck will use two of its manufacturing facilities in the effort, supporting drug substance development, formulation and vial filling. Merck's Hilleman Center campus in Durham. “This site is preparing to produce bulk drug substance for the J&J’s vaccine.”Įven though two vaccine candidates under development by Merck failed to pass muster in clinical trials recently, Merck agreed with federal officials to cooperate with J&J and combine Merck’s world-class biomanufacturing capabilities with J&J’s to help whack the scourge of COVID-19. “Our Durham, NC facility is part of Merck’s global manufacturing network,” the company said in a statement. Hilleman Center for Vaccine Manufacturing in Durham was joining the scramble to produce a share of the hundreds of millions of doses needed to quell the pandemic. In a two-sentence statement issued Wednesday evening, Merck put an end to rumors that the massive Maurice R. Compare Standard and Premium Digital here.Īny changes made can be done at any time and will become effective at the end of the trial period, allowing you to retain full access for 4 weeks, even if you downgrade or cancel.Global pharmaceutical giant Merck has confirmed that its flagship Durham vaccine manufacturing facility is gearing up to help competitor Johnson & Johnson produce COVID-19 vaccine. You may also opt to downgrade to Standard Digital, a robust journalistic offering that fulfils many user’s needs. If you’d like to retain your premium access and save 20%, you can opt to pay annually at the end of the trial. If you do nothing, you will be auto-enrolled in our premium digital monthly subscription plan and retain complete access for $69 per month.įor cost savings, you can change your plan at any time online in the “Settings & Account” section. For a full comparison of Standard and Premium Digital, click here.Ĭhange the plan you will roll onto at any time during your trial by visiting the “Settings & Account” section. Premium Digital includes access to our premier business column, Lex, as well as 15 curated newsletters covering key business themes with original, in-depth reporting. Standard Digital includes access to a wealth of global news, analysis and expert opinion. During your trial you will have complete digital access to FT.com with everything in both of our Standard Digital and Premium Digital packages.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |